PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
| Autor: | Melissa Bersanelli, Francesco Bonatti, Sebastiano Buti, Agnese Cosenza, Paola Bordi, Roberta Minari, Marcello Tiseo, Francesco Facchinetti, Gloria Cinquegrani, Andrea Ardizzoni, Elena Rapacchi, Leonarda Ferri, Alessandro Leonetti, Federico Quaini, Alessandra Dodi, Giulia Mazzaschi, Anna Squadrilli, Francesco Gelsomino |
|---|---|
| Přispěvatelé: | Minari R., Bonatti F., Mazzaschi G., Dodi A., Facchinetti F., Gelsomino F., Cinquegrani G., Squadrilli A., Bordi P., Buti S., Bersanelli M., Leonetti A., Cosenza A., Ferri L., Rapacchi E., Quaini F., Ardizzoni A., Tiseo M. |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
PD-L1 Adult Male Cancer Research medicine.medical_specialty medicine.medical_treatment Immune checkpoint inhibitors Programmed Cell Death 1 Receptor Single-nucleotide polymorphism NSCLC Polymorphism Single Nucleotide B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Internal medicine Carcinoma Non-Small-Cell Lung Biomarkers Tumor Medicine Humans In patient CTLA-4 Antigen 030212 general & internal medicine Immune Checkpoint Inhibitors Aged Neoplasm Staging Aged 80 and over biology business.industry General Medicine Immunotherapy Middle Aged Progression-Free Survival Treatment Outcome 030220 oncology & carcinogenesis biology.protein Biomarker (medicine) biomarker Female immunotherapy business SNPs |
| Zdroj: | Tumori. 108(1) |
| ISSN: | 2038-2529 |
| Popis: | Objective: To investigate the role of CTLA-4, PD-1 (programmed death-1), and PD-L1 (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods: A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups. Results: Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, PD-L1 rs4143815 SNP and the long clinical benefit group showed a statistically significant association ( p = 0.02). The nonresponder cohort displayed distinctive PD-L1 haplotype ( p = 0.05). Conclusion: PD-L1 SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|